BiotechTube

Cushing's syndrome confirmation

Pre-clinicalTerminated
0 views this week 0 watching💤 Quiet
Interest: 15/100
15
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Cushing's Syndrome

Conditions

Cushing's Syndrome

Trial Timeline

Feb 1, 2009 → —

NCT ID
NCT00796783

About Cushing's syndrome confirmation

Cushing's syndrome confirmation is a pre-clinical stage product being developed by Corcept Therapeutics for Cushing's Syndrome. The current trial status is terminated. This product is registered under clinical trial identifier NCT00796783. Target conditions include Cushing's Syndrome.

What happened to similar drugs?

2 of 10 similar drugs in Cushing's Syndrome were approved

Approved (2) Terminated (1) Active (7)
🔄pasireotide LAR + SOM230 LAR 30 mg + SOM230 LAR 10 mgNovartisPhase 3
🔄Pasireotide sub-cutaneousNovartisPhase 3
🔄osilodrostat + osilodrostat PlaceboNovartisPhase 3
🔄PasireotideNovartisPhase 3
✅Pasireotide s.c. + Sitagliptin + Liraglutide + Insulin + Pasireotide LAR + MetforminNovartisApproved
✅Pasireotide + Cabergoline + Pasireotide LARRecordatiApproved
🔄mifepristoneCorcept TherapeuticsPhase 3

Hype Score Breakdown

Clinical
3
Activity
0
Company
12
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00796783Pre-clinicalTerminated

Competing Products

18 competing products in Cushing's Syndrome

See all competitors
ProductCompanyStageHype Score
AZD4017 and prednisolone + Placebo Oral Tablet and prednisoloneAstraZenecaPhase 2
35
pasireotide LAR + SOM230 LAR 30 mg + SOM230 LAR 10 mgNovartisPhase 3
40
Pasireotide sub-cutaneousNovartisPhase 3
40
osilodrostat + osilodrostat PlaceboNovartisPhase 3
40
OsilodrostatNovartisPhase 2
35
PasireotideNovartisPhase 3
40
Pasireotide s.c. + Sitagliptin + Liraglutide + Insulin + Pasireotide LAR + MetforminNovartisApproved
43
SOM230 s.c.NovartisPhase 2
35
Lu AG13909LundbeckPhase 2
39
OsilodrostatRecordatiPre-clinical
23
Pasireotide + Cabergoline + Pasireotide LARRecordatiApproved
40
osilodrostatRecordatiPhase 2
32
OsilodrostatRecordatiPre-clinical
27
mifepristoneCorcept TherapeuticsPhase 3
37
CORT125134Corcept TherapeuticsPhase 2
32
MifepristoneCorcept TherapeuticsPhase 3
37
mifepristoneCorcept TherapeuticsPhase 3
37
mifepristoneCorcept TherapeuticsPhase 3
29